[go: up one dir, main page]

WO1990001046A1 - Compositions et procede de formation in situ de films sur du tissu corporel - Google Patents

Compositions et procede de formation in situ de films sur du tissu corporel Download PDF

Info

Publication number
WO1990001046A1
WO1990001046A1 PCT/US1989/003216 US8903216W WO9001046A1 WO 1990001046 A1 WO1990001046 A1 WO 1990001046A1 US 8903216 W US8903216 W US 8903216W WO 9001046 A1 WO9001046 A1 WO 9001046A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
hydroxypropyl cellulose
film
compositions
body tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1989/003216
Other languages
English (en)
Inventor
Edwin Pomerantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zila Pharmaceuticals Inc
Original Assignee
Zila Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1019900700612A priority Critical patent/KR940011240B1/ko
Priority to JP1508648A priority patent/JP3000104B2/ja
Priority to MX2168690A priority patent/MX21686A/es
Priority to BR909002342A priority patent/BR9002342A/pt
Application filed by Zila Pharmaceuticals Inc filed Critical Zila Pharmaceuticals Inc
Publication of WO1990001046A1 publication Critical patent/WO1990001046A1/fr
Priority to NZ232625A priority patent/NZ232625A/xx
Priority to FI901443A priority patent/FI901443A0/fi
Priority to DK199000753A priority patent/DK175653B1/da
Priority to NO901346A priority patent/NO180618C/no
Priority to CN90101988A priority patent/CN1038227C/zh
Priority to IE209690A priority patent/IE902096A1/en
Priority to ES909001992A priority patent/ES2020655A6/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D101/00—Coating compositions based on cellulose, modified cellulose, or cellulose derivatives
    • C09D101/08—Cellulose derivatives
    • C09D101/26—Cellulose ethers
    • C09D101/28—Alkyl ethers
    • C09D101/284—Alkyl ethers with hydroxylated hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on

Definitions

  • This invention relates to compositions and methods for in situ treatment of body tissues.
  • the invention pertains to the use of hydroxypropyl cellulose (HPC) in the manufacture of such compositions and the use of such compositions, manufactured from HPC.
  • HPC hydroxypropyl cellulose
  • the invention relates to methods of treating skin, mucosal tissue and other moist tissue, by forming an adherent film thereon.
  • the invention in another respect, relates to compositions and methods for forming films in situ on body tissues, which films are effective sustained release carriers for medicinal and cosmetic components, to maintain such medicaments at and on a treatment site on body tissue.
  • topical anesthetics for reducing pain
  • commercially-available preparations containing benzocaine are widely used.
  • these do not form coherent films in the mouth and are easily displaced from the ulcer site by saliva and physical movement of the surrounding tissues.
  • An intra-oral ointment base for use in the oral cavity has been proposed which consists essentially of sodium carboxy ethyl cellulose and pectin.
  • such ointments are not considered sufficiently persistent to solve the basic problem of maintaining a topical analgesic agent in contact with an ulcer for up to several hours.
  • Topical adhesive dosages for mucosal ulcers have also been proposed in the form of a two-phase tablet having an adhesive peripheral layer of hydroxypropyl cellulose with the medication carried in an oleaginous core of cocoa butter. This device adheres to the ucosa of dogs for thirty minutes to six hours.
  • HPC hydroxypropyl cellulose
  • polyvinylacetate hydroxypropyl cellulose
  • Precast films of hydroxypropyl cellulose containing analgesics and antibiotics has been reported anecdotally fur the treatment of pain of leukoplakia.
  • Alkyl cellulose and/or cellulose ether compounds have been used as thickeners or ointment bases for a wide variety of medicaments.
  • an alkyl cellulose believed to be methyl cellulose, was used as a carrier and ointment base for the topical medicinal composition described in U.S. Patent No. 4,381,296 to Tinnell.
  • Hydroxyethyl cellulose and/or hydroxypropyl cellulose was used to form .a gel for application of the topical acne medications of U.S. Patent No. 4,244,948 to Boghosian et al.
  • a water-soluble film formed of hydroxypropyl cellulose was used as the carrier for a bactericide in a teat-dip composition in U.S. Patent No. 4,434,181 to Marks et al.
  • the cellulosic component of the commercially available gels containing the Tinnell , 296 medicaments is, in fact, hydroxypropyl cellulose, rather than methylcellulose as previously understood
  • the mechanism of film formation is specific to hydroxypropyl cellulose.
  • Closely related alkyl or hydroxyalkyl-substituted cellulose, such as methylcellulose, hydroxyethyl cellulose and hydroxybutyl cellulose are not suitable substitutes for HPC.
  • the barrier effect of the film derived from HPC provides practically instantaneous and long-lasting substantial reduction of the pain associated with aphthous and other ulcers and trauma. This pain relief and prevention activity by the barrier action of the film is very surprising in view of the previous belief that is was necessary to provide an analgesic, e.g., benzocaine, at the ulcer site.
  • compositions for forming the HPC-derived films in situ on body tissues can also function as stable carriers for a wide variety of medicinal components.
  • the medicinal components are incorporated in the resulting in situ formed films, from which they are released to provide a sustained supply of the medicine at the treatment site.
  • HPC in the manufacture of a film-forming composition for topical treatment of human tissue.
  • the composition comprises hydroxypropyl cellulose, an esterification agent, and a suitable volatile solvent which functions as a medium for reaction of the HPC and the acid and also to maintain the esterification reaction product in the form of a gel or lotion for convenient application.
  • Such compositions are especially adapted to treatment of trauma of skin and mucosal tissue from external causes, e.g. cuts, abrasions, incisions and burns, as well as bacterial and fungal infections and ulcers of unknown etiology.
  • the solvent is alcoholic, e.g. ethyl, isopropyl or methyl alcohol.
  • the specific solvent is chosen for its ability to dissolve the HPC and esterificaticn agent and to maintain the esterification reaction product in solution or suspension until application of the composition to the treatment site. Obviously, the solvent should not be toxic to the body in the quantities employed.
  • the esterification agent can, advantageously, be a weak carboxylic acid which is substantially non-toxic.
  • the specific acid or acids are selected for their ability to react with the HPC to form an esterification reaction product (see below) which is soluble in the reaction mixture at storage temperatures, e.g. 40-80 degrees Fahrenheit, but which is insoluble in body fluids at or near body temperatures and above.
  • Suitable weak organic acids include salicylic acid and tannic acid and mixtures thereof.
  • Other suitable esterification agents can be identified by those skilled in the art, having regard for this disclosure.
  • compositions which comprise the film-forming compositions described above and a biologically active topical treatment component, cosmetics, or medication.
  • the biologically active component is physically incorporated in the film-forming components and in the films formed therefrom, to provide medically effective quantities of the topical agent at the treatment site on body tissue.
  • the incorporated biologically active components are thus maintained in contact with the tissue for a time effective to treat the medical condition for which they are intended, rather than being displaced by physical movement of the tissue, abrasion or by irrigation by body fluids.
  • the films provide a sustained release mechanism which increases the efficacy of the treatment.
  • the HPC derived films are inert and do not interfere with the normal action of the topical treatment agent.
  • the esterification component of the compositions esterifies at least a portion of the HPC.
  • This esterification reaction apparently takes place primarily upon drying of the solvent carrier.
  • the HPC and acid components of my composition, as well as any ester derivative which may form in solution prior to application of the composition to the body tissue are soluble in the solvent carrier at room temperature under normal pre-application and storage conditions.
  • a film is formed in situ which is insoluble in body fluids at and above normal body temperature of about 37 degrees centigrade.
  • I also incorporate a non-toxic weak cross-linking agent in the compositions of the invention.
  • the resultant in situ formed film is somewhat tougher and more resilient and has better adhesion to body tissue than such films which are formed from compositions without such cross-linking agent.
  • the agents for cellulosic compounds, the specific agent being chosen so as to avoid premature formation of an insoluble mass prior to application of the composition.
  • boric acid is an appropriately effective cross- linking agent for use in practicing the present invention. While I do not wish to be bound by this mechanism, it appears that the cross-linking agent effectively bonds some of the un- esterified hydroxyl groups into the film formed on drying of the composition after application to the body issue.
  • HPC-derived films are soluble in ethyl alcohol and similar non-toxic volatile solvents, e.g., isopropyl alcohol and the like, but are insoluble in water and water- containing body fluids, e.g., saliva at normal human body temperature. Films formed by evaporation of the solutions are tough, resilient and adhesive to body tissues and form a protective barrier against air, other body fluids and foreign substances.
  • the cellulosic compound which is reacted with weak carboxylic acids to form the film according to my invention, is selected for its ability to react with the carboxylic acid component to form a film which is insoluble in water and aqueous body fluids at a temperature equal to or greater than body temperature.
  • hydroxypropyl cellulose HPC
  • Such cellulosic compound is available commerically, for example, the product sold under the name "Klucel 1 *, a registered trademark of Aqualon Company.
  • the type ⁇ MF" Klucel product is particularly suitable.
  • the solvent for forming the solutions of the HPC is selected for its ability to dissolve the HPC and HPC esters and its non-toxic characteristics when the composition is applied in the amount necessary to from a protective film.
  • ethyl alcohol is preferred when the film is to be deposited in the oral cavity whereas isopropyl alcohol is suitable for use in depositing films on the skin.
  • suitable solvents will be readily identified by those skilled in the art having a regard for he disclosures herein, e.g.. volatile polar solvents which are medically compatible with body tissue.
  • the specific esterification agent component of the compositions is chosen for its ability to react with the HPC to form, upon air-drying of the composition, a tough resilient film which adheres to body tissue.
  • Strong carboxylic acids e.g., acetic acid, citric acid and the like do not provide this result.
  • weak carboxylic acids, especially salicylic acid, tannic acid and the like and mixture thereof function effectively.
  • the in situ film formation capability appears to be related to the solubility of the HPC derivative in water and aqueous body fluids at body temperature.
  • any such weak carboxylic acid which is non-toxic and has the capability to form such insoluble films can be effectively employed, the selection of such weak acid being within the capability of persons skilled in this art, having regard for this disclosure.
  • Salicylic acid and tannic acid have been identified as particularly effective in the practice of my invention.
  • a mixture of these two acids in the film forming compositions of the invention produce a superior film in terms of adhesion and mechanical integrity, although either of these acids alone provides an effective in situ deposited film.
  • the film of HPC which is formed by evaporation of the compositions is apparently a "physical film", i.e., the cellulosic compounds do not polymerize.
  • Evidence of the physical characteristics of these films is provided by the fact that such film, once formed, simply re-dissolves upon further application of the compositions to the same site.
  • the film forming composition can be applied to the body tissue by any convenient technique, e.g., spraying. dipping or simple direct application by a swab.
  • the HPC component is present in the solution in an amount from about 0.1 - 20% by weight of the final composition.
  • the proportion of the HPC in the composition affects the time required for the composition to air dry and form the tough adhesive film.
  • the composition dries more slowly, but he resultant film is more coherent and abrasion-resisitant.
  • the film forms more quickly by air drying, but the resultant film is less coherent and adhesive owing to the fact that the portion of the film at the surface of the applied composition and at the body tissue surface dries at different rates.
  • the carboxylic acid component of the composition can be a single acid, alone or in combination with other weak carboxylic acids. Whether present alone or in combination, however, the proportion of the carboxylic acid can vary from about 1 to about 10% by weight of the composition with the optimum concentration being closer to the upper portion of this range. Indeed, there are indications that higher proportions of the carboxylic acids do not appreciably interfere with the film formation. In the lower range, the film forms more slowly and is less coherent.
  • compositions are applied typically in localized areas, to the body tissue and air-dried to form the film in situ, adhesively secured to the tissue.
  • steps should be taken to remove as much of the water, moisture or other body fluids from the surface of the body tissue before applying the composition.
  • normal dental procedures for substantially drying the mucosal tissue are employed and air is drawn or blown over the surface of the applied composition to promote more rapid evaporation of the solvent and formation of the film.
  • compositions have been found especially useful in the treatment of aphthous ulcers of the mucosa, including recurrent aphthous stomatitis.
  • This treatment provides essentially immediate and long-lasting relief of the extraordinar pain associated with such ulcers in the formative and pre- localizing steps.
  • the particular composition which has been found most effective in alleviating such pain includes HPC, ethyl alcohol solvent, a mixture of tannic and salicylic acids as the weak carboxylic acid component and boric acid as the cross-linking agent.
  • HPC ethyl alcohol solvent
  • a mixture of tannic and salicylic acids as the weak carboxylic acid component
  • boric acid as the cross-linking agent.
  • the composition is applied directly to the surface of the ulcer and surrounding mucosa with a swab and is air dried by simply ensuring that the patient breathes normally through the mouth.
  • the film is adhesively retained on the ulcer site and surrounding mucosal tissue for extended periods of time, upwards of several hours. Furthermore, the initial pain relief, obtained by the exclusion of air, saliva, etc. , from the ulcer, continues during this extended retension period and even prevents recurrence of the pain despite repeated attempts to cause pain onset by deliberately insulting the ulcer with irritating foods such as orange juice.
  • EXAMPLE 1 EXAMPLE 1 ;
  • a composition is prepared by mixing the following components in the indicated proportions:
  • Example 1 The composition of Example 1 is tested for pain reduction capability in comparison with the commerically available medication sold under the name "Orabase", a composition containing benzocaine in a sodium carboxymethyl cellulose and pectin base.
  • Comparable test sites consisting of an aphthous ulcer and surrounding healthy mucosal tissue is selected in the mouths of each of the subjects. These sites are prepared by irrigating with distilled water and then carefully drying with cotton gauze pads.
  • composition prepared according to this example is applied as a thin coating to the prepared aphthous ulcer sites in the mouths of the test group and a similar thin coating of the Orbase control medication is applied to aphthous ulcer sites in the mouths of the control group.
  • Example 1 The patients of both the test group and the control group are required to breathe normally through the mouth for a period of two minutes, after which point it is noted that the composition of Example 1 has dried in the mouths of the test .”group patients to form a film over the aphthous ulcer site.
  • test and control patients Observation of the test and control patients demonstrates that the films of the test composition are still present in place in 80% of the test subjects*' mouths two hours after application, whereas the control medication completely disappears from the ulcer sites in all subjects in the control group.
  • Example 2 The procedure of Example 2 is repeated except that, just prior to the preparation of the ulcer sites, the aphthous ulcers in the mouths of both the test and control patients are insulted by application of orange juice. The incidence of pain is clinically observed for a period of one hour, at which time the treated ulcer sites are once again insulted with orange juice. Pain observation is continued for an additional three hours.
  • both the test and control groups all patients experience a large increase in pain after the first insult, followed by a mild to significant decrease in pain after the immediate application of both the test and control compositions.
  • the patients in the test group which are treated with the composition of the present invention experience no increase in pain and continue to experience mild to substantial pain reduction for the succeeding three hours.
  • the patients in the control group experience a large increase in pain at the second insult which decreases only slightly during the ensuing three hours.
  • compositions contain, respectively, 10% tannic acid, 10% salicylic acid and 7% boric acid. Both of these compositions yield comparable results to those set forth in Examples 2 and 3.
  • the boric acid cross-linking agent is omitted from the compositions of the preceeding Examples.
  • the in situ deposited films formed from these compositions actually comprise two layers which can be mechanically separated. Although these two-layer films are effective in pain treatment, they are less persistent.
  • compositions of Example 1 Therapeutically effective quantities of various topical medicines are incorporated into the compositions of Example 1.
  • the resulting mixtures are shelf-stable and are topically applied to body tissue and air-dried, forming resilient adherent films containing the medicaments, which migrate to the treatment site to effectively accomplish the desired treatment.
  • the flexural aspect of a subject's forearms are cleansed and approximately 10 mg of the test material is applied to a clearly marked 8 cm 2 area.
  • Four formulations are evaluated on four different 8 cm areas on each arm, totaling eight formulations per subject. The formulations are applied at 4 p.m. and allowed to remain in place overnight. At 8 a.m. the test sites are gently washed with soap and water and read two hours after washing. The intensity of blanching is determined on a four-point scale. Twenty subjects were used to evaluate a panel of eight formulations, with a ventilated guard placed over the test sites and ten subjects were used to evaluate the formulations with no guard placed over the test sites. The formulations tested were:
  • Example 1 The ability of the film forming compositions of Example 1 to carry and effectively release antibiotics was demonstrated by incorporating 1% neomycin therein. This formulation was compared to a commerical 1% neomycin cream by applying the formulations to hairless mouse skins (10 replications) and agar plates (4 replications) inoculated with staph. aureus. The radio of inhibitions (mm) of each replicate were summed to give a total score for each formulation. The results were: Mouse Skin A ⁇ ur Plate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

On forme des films protecteurs in situ sur du tissu corporel par application et séchage par air d'une composition comprenant (a) de la cellulose d'hydroxypropyle, (b) un agent d'estérification réagissant avec la cellulose d'hydroxypropyle pour former un produit de réaction soluble dans le solvant de (c) mais insoluble dans des fluides corporels aux températures du corps, et (c) un solvant volatile non toxique pour ladite cellulose d'hydroxypropyle et ledit produit de réaction. Les films sont forts, souples et adhérent au tissu corporel y compris à la muqueuse.
PCT/US1989/003216 1988-05-02 1989-07-24 Compositions et procede de formation in situ de films sur du tissu corporel Ceased WO1990001046A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1019900700612A KR940011240B1 (ko) 1988-05-02 1989-07-24 약제학적 피막 형성 조성물
JP1508648A JP3000104B2 (ja) 1988-05-02 1989-07-24 身体組織上の本来の部位にフィルムを形成する組成物及び方法
MX2168690A MX21686A (es) 1988-05-02 1989-07-24 Composicion formadora de pelicula util para tratamientos topicos.
BR909002342A BR9002342A (pt) 1988-05-02 1989-07-24 Composicao de hidroxipropil celulose formadora de pelicula,composicao para formacao in situ de peliculas de medicamentos no tecido corporeo e processo para formacao desta
NZ232625A NZ232625A (en) 1988-05-02 1990-02-21 Compositions comprising hydroxypropyl cellulose and an esterification agent for producing a skin-covering film
FI901443A FI901443A0 (fi) 1988-05-02 1990-03-22 Sammansaettningar och lokala foerfarande foer forming av en film pao kropps vaevande.
DK199000753A DK175653B1 (da) 1988-07-25 1990-03-22 Fremgangsmåde til fremstilling af præparater, som in situ danner film på legemsvæv
NO901346A NO180618C (no) 1988-05-02 1990-03-23 Fremgangsmåte for fremstilling av preparater som in situ danner filmer på kroppsvev
CN90101988A CN1038227C (zh) 1988-05-02 1990-04-10 在人体组织上用于治疗的成膜制剂的制造方法
IE209690A IE902096A1 (en) 1988-05-02 1990-06-11 Compositions and in situ methods for forming films of body¹tissue
ES909001992A ES2020655A6 (es) 1988-05-02 1990-07-24 Procedimiento de obtencion de composiciones formadoras de pelicula sobre tejidos corporales.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903288A 1988-05-02 1988-05-02
USPCT/US88/02515 1988-07-25

Publications (1)

Publication Number Publication Date
WO1990001046A1 true WO1990001046A1 (fr) 1990-02-08

Family

ID=22695630

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1988/002515 Ceased WO1989010745A1 (fr) 1988-05-02 1988-07-25 Compositions et procedes in situ pour la formation de pellicules sur des tissus du corps
PCT/US1989/003216 Ceased WO1990001046A1 (fr) 1988-05-02 1989-07-24 Compositions et procede de formation in situ de films sur du tissu corporel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1988/002515 Ceased WO1989010745A1 (fr) 1988-05-02 1988-07-25 Compositions et procedes in situ pour la formation de pellicules sur des tissus du corps

Country Status (14)

Country Link
EP (1) EP0380647A4 (fr)
JP (1) JP3000104B2 (fr)
KR (1) KR940011240B1 (fr)
CN (1) CN1038227C (fr)
AU (2) AU2252388A (fr)
BR (1) BR9002342A (fr)
CA (1) CA1337396C (fr)
ES (1) ES2020655A6 (fr)
FI (1) FI901443A0 (fr)
IE (1) IE902096A1 (fr)
MX (1) MX21686A (fr)
NO (1) NO180618C (fr)
NZ (1) NZ232625A (fr)
WO (2) WO1989010745A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5425953A (en) * 1991-04-23 1995-06-20 Perio Products Limited Polymer composition for tooth bleaching and other dental uses thereof
WO1999004764A1 (fr) * 1997-07-23 1999-02-04 Perio Products Ltd. Compositions d'acide tannique et de polymeres pour la liberation contrôlee d'agents pharmaceutiques, notamment dans la cavite buccale
WO1999016417A1 (fr) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Pulverisation ou capsule buccale, polaire et non polaire
US6969508B2 (en) 1997-10-01 2005-11-29 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
WO2012175879A1 (fr) * 2011-06-22 2012-12-27 Laboratoires Urgo Composition filmogène et son utilisation pour le traitement de l'herpès
EP2742931A1 (fr) * 2012-12-13 2014-06-18 LTS LOHMANN Therapie-Systeme AG Médicament topique destiné au traitement d'aphtes
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010745A1 (fr) * 1988-05-02 1989-11-16 Pomerantz, Edwin Compositions et procedes in situ pour la formation de pellicules sur des tissus du corps
GR1001331B (el) * 1990-07-18 1993-08-31 Zila Pharm Inc Συνθεσεις και μεθοδοι επιτοπιου σχηματισμου μεμβρανων επι ιστων του σωματος.
FR2773068B1 (fr) * 1997-12-29 2000-09-01 Oreal Composition cosmetique filmogene a base d'un derive de cellulose contenant, en tant qu'agent epaississant, un tetraborate de metal alcalin
US6283933B1 (en) 1998-12-23 2001-09-04 Closure Medical Corporation Applicator for dispensable liquids
US6595940B1 (en) 1998-12-23 2003-07-22 Closure Medical Corporation Applicator for dispensable liquids
US20020064542A1 (en) * 1999-06-29 2002-05-30 George Endel Deckner Tissue products utilizing water soluble films as carriers for antiviral compositions and process for making
CN1891300B (zh) * 2005-07-06 2010-04-14 上海医药工业研究院 苯佐卡因成膜凝胶组合物及其用途
CN100446814C (zh) * 2005-07-22 2008-12-31 上海医药工业研究院 复方硝酸益康唑成膜凝胶组合物及其制药用途
CN101138543B (zh) * 2006-09-06 2012-01-04 上海医药工业研究院 积雪草总苷局部成膜凝胶组合物及其应用
CN101190178B (zh) * 2006-11-24 2010-05-12 上海医药工业研究院 抗病毒局部成膜凝胶组合物
CN104337939A (zh) * 2013-08-05 2015-02-11 天津司威林医疗器械科技有限公司 一种中药止血涂膜材料的制备方法
CN104997723A (zh) * 2014-04-16 2015-10-28 上海现代药物制剂工程研究中心有限公司 成膜凝胶组合物、其用途及药物成膜凝胶组合物
CN105012960A (zh) * 2014-04-16 2015-11-04 上海现代药物制剂工程研究中心有限公司 成膜凝胶组合物、其用途及护创材料
CN110201218A (zh) * 2018-12-23 2019-09-06 山东泰开制药有限公司 液体创可贴及其制备方法
US20220287981A1 (en) * 2019-08-16 2022-09-15 Amd Pharma Ltd. Adhesive drug delivery microparticles and a product comprising thereof
WO2021132199A1 (fr) * 2019-12-26 2021-07-01 帝人ファーマ株式会社 Pansement médical
FR3117357B1 (fr) * 2020-12-15 2023-05-26 Oreal Procédé de revêtement des matières kératiniques consistant à appliquer un agent de revêtement formé par liaisons hydrogène d’un polyphénol avec un composé apte à réagir avec celui-ci

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244948A (en) * 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
US4256752A (en) * 1978-02-17 1981-03-17 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler Treatment of ulcers with acylated aminoalkyl cyanoguanidines containing a heterocyclic residue
US4381296A (en) * 1980-06-23 1983-04-26 Tinnell James E Treatment for herpes virus
US4434181A (en) * 1981-12-07 1984-02-28 Fearing Manufacturing Co., Inc. Teat dip
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4695464A (en) * 1984-10-09 1987-09-22 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US438129A (en) * 1890-10-07 Geoege henesy flint
NL31756C (fr) * 1962-04-26
US3591680A (en) * 1969-11-17 1971-07-06 Smith Kline French Lab Concentrated antacid compositions and method of producing antacid activity
JPS5540604A (en) * 1978-09-14 1980-03-22 Mitsui Toatsu Chem Inc Improved local topicum
US4283393A (en) 1979-03-13 1981-08-11 Merck & Co., Inc. Topical application of interferon inducers
US4307075A (en) * 1979-09-13 1981-12-22 American Home Products Corporation Topical treatment of aphthous stomatitis
JPS5927818A (ja) * 1982-08-09 1984-02-14 Nippon Soda Co Ltd 人工唾液
JPS6187603A (ja) * 1984-06-09 1986-05-06 Earth Chem Corp Ltd ダニ防除剤
JPS6263513A (ja) * 1985-09-13 1987-03-20 Nippon Shinyaku Co Ltd フイルム製剤
JPS62270503A (ja) * 1986-05-20 1987-11-24 Nippon Soda Co Ltd シ−ト状又はフイルム状消毒剤及びその製法
WO1989010745A1 (fr) * 1988-05-02 1989-11-16 Pomerantz, Edwin Compositions et procedes in situ pour la formation de pellicules sur des tissus du corps

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256752A (en) * 1978-02-17 1981-03-17 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler Treatment of ulcers with acylated aminoalkyl cyanoguanidines containing a heterocyclic residue
US4244948A (en) * 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
US4381296A (en) * 1980-06-23 1983-04-26 Tinnell James E Treatment for herpes virus
US4434181A (en) * 1981-12-07 1984-02-28 Fearing Manufacturing Co., Inc. Teat dip
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4695464A (en) * 1984-10-09 1987-09-22 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0380647A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5425953A (en) * 1991-04-23 1995-06-20 Perio Products Limited Polymer composition for tooth bleaching and other dental uses thereof
WO1999004764A1 (fr) * 1997-07-23 1999-02-04 Perio Products Ltd. Compositions d'acide tannique et de polymeres pour la liberation contrôlee d'agents pharmaceutiques, notamment dans la cavite buccale
US6998110B2 (en) 1997-10-01 2006-02-14 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule
US6676931B2 (en) 1997-10-01 2004-01-13 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US6969508B2 (en) 1997-10-01 2005-11-29 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999016417A1 (fr) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Pulverisation ou capsule buccale, polaire et non polaire
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron
WO2012175879A1 (fr) * 2011-06-22 2012-12-27 Laboratoires Urgo Composition filmogène et son utilisation pour le traitement de l'herpès
US9226989B2 (en) 2011-06-22 2016-01-05 Laboratoires Urgo Film-forming composition, and use thereof for treating herpes
EP2742931A1 (fr) * 2012-12-13 2014-06-18 LTS LOHMANN Therapie-Systeme AG Médicament topique destiné au traitement d'aphtes
WO2014090981A1 (fr) * 2012-12-13 2014-06-19 Lts Lohmann Therapie-Systeme Ag Médicament topique utilisé pour le traitement des aphtes

Also Published As

Publication number Publication date
EP0380647A4 (en) 1991-07-24
IE902096A1 (en) 1991-06-19
JP3000104B2 (ja) 2000-01-17
AU2252388A (en) 1989-11-29
AU614179B2 (en) 1991-08-22
BR9002342A (pt) 1991-08-06
WO1989010745A1 (fr) 1989-11-16
NO180618C (no) 1997-05-21
AU4053689A (en) 1990-02-19
ES2020655A6 (es) 1991-08-16
JPH03503052A (ja) 1991-07-11
KR940011240B1 (ko) 1994-12-03
NO901346D0 (no) 1990-03-23
NO901346L (no) 1990-03-23
FI901443A0 (fi) 1990-03-22
NO180618B (no) 1997-02-10
KR900701251A (ko) 1990-12-01
EP0380647A1 (fr) 1990-08-08
NZ232625A (en) 1991-08-27
MX21686A (es) 1994-01-31
CA1337396C (fr) 1995-10-24
CN1038227C (zh) 1998-05-06
CN1048979A (zh) 1991-02-06

Similar Documents

Publication Publication Date Title
US5081158A (en) Compositions and in situ methods for forming films on body tissue
US5081157A (en) Compositions and in situ methods for forming films on body tissue
CA1337396C (fr) Compositions et methodes in situ pour former des pellicules sur les tissus humains
JP2735392B2 (ja) 乾癬の治療法
EP0247142B1 (fr) Vehicules pharmaceutiques filmogenes pour l'application de medicaments sur les ongles, compositions pharmaceutiques a base de ces vehicules, et leurs procedes d'utilisation
US5906814A (en) Topical film-forming compositions
US4210633A (en) Flurandrenolide film formulation
US4466956A (en) Method of therapy for oral herpes simplex
US5462728A (en) Pharmaceutical compositions
US5800831A (en) Psoriasis treatment with polymer film
DK175653B1 (da) Fremgangsmåde til fremstilling af præparater, som in situ danner film på legemsvæv
DE69922471T2 (de) Topische Borneol und Wismutgallat enthaltende pharmazeutische Zubereitungen zur Wundheilung
US7651681B1 (en) Method and compositions for in situ formation of protective and/or medicated films on body tissue
US3592891A (en) Method of treating lesions of the oral orifice
CN101138543B (zh) 积雪草总苷局部成膜凝胶组合物及其应用
CN1891300B (zh) 苯佐卡因成膜凝胶组合物及其用途
CN101138541B (zh) 氨来占诺局部成膜凝胶组合物及其应用
KR100589946B1 (ko) 약물 서방형 치약조성물
KR100483227B1 (ko) 푸시딘산외용분사제조성물
AU664419B2 (en) Use of sulphated sugars
US6113893A (en) Psoriasis treatment
MXPA00003491A (en) Method and compositions for in situ
IL89935A (en) Composition for treating afflictions of the oral cavity
JPH0639384B2 (ja) 褥瘡の予防治療用組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR DK JP KR NO US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989909293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989909293

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989909293

Country of ref document: EP